SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is trending as silver prices approach all-time highs, fueled by speculation around potential Fed rate cuts and renewed interest in precious metals as a hedge against economic uncertainty. Community members are discussing technical breakouts, potential for a silver squeeze, and historical inflation-adjusted valuations, while some express concerns about market manipulation and potential pullbacks. The broader context involves increased industrial demand for silver and its role as a safe-haven asset amid global economic concerns.

Abaxx Technologies, Inc. development-stage financial technology company, which develops software tools that enable commodity traders and finance professionals to communicate trade and transact faster and more securely. Its software technologies include deep learning and natural language processing (DL/NPL), self-sovereign digital identity (SSI), encrypted content-addressing distributed file systems, smart contracting languages and protocols, and decentralized datastore technology (DDS). The company was founded by Joshua Dale Crumb, Thomas McMahon and Andrew Fedak on January 25, 2018 and is headquartered in Toronto, Canada.

Abaxx Technologies Inc

Recent news and partnerships are driving interest in Abaxx, with community members pointing to its potential to disrupt commodity markets. Many are drawing comparisons to Nvidia and Palantir, highlighting the company's innovative approach and future growth potential. The discussion also revolves around the anticipation of upcoming milestones and the impact on the stock's valuation.

ConocoPhillips is an exploration and production company, which engages in the exploration, production, transport, and marketing of crude oil, bitumen, and natural gas. It operates through the following geographical segments: Alaska, Lower 48, Canada, Europe, Middle East, and North Africa, Asia Pacific, and Other International. The Alaska segment explores for, produces, transports and markets crude oil, natural gas and NGLs. The Lower 48 segment consists of operations located in the 48 contiguous U.S. states and the Gulf of Mexico. The Canada segment refers to oil sands development in the Athabasca Region of northeastern Alberta and a liquids-rich unconventional play in western Canada. The Europe, Middle East, and North Africa segment includes operations in the Norwegian sector of the North Sea, the Norwegian Sea, Qatar, Libya, Equatorial Guinea and commercial and terminalling operations in the U.K. The Asia Pacific segment focuses on explorations and product operations in China, Indonesia, Malaysia, and Australia. The Other International segment handles exploration activities in Columbia and Argentina. The company was founded by Isaac Elder Blake on November 25, 1875 and is headquartered in Houston, TX.

Conoco Phillips

ConocoPhillips is trending due to discussions around options trading strategies, potential undervaluation, and analyst ratings. Community members are weighing the company's stability against its risk profile compared to peers like ExxonMobil, while also considering its dividend yield as a factor for investment. Option traders are actively discussing potential entry and exit points.

Global X Funds - Global X Funds Global X Robotics & Artificial Intelligence ETF

Global X Funds Global X Robotics & Artificial Intelligence ETF

$BOTZ is trending as investors weigh the potential of AI and robotics against concerns of a possible tech bubble and broader economic weakness. Discussions revolve around the ETF's key holdings, including NVDA, and its exposure to the US-China AI arms race, with community members analyzing its long-term growth prospects.

Morgan Stanley operates as a global financial services company. The firm provides investment banking products and services to its clients and customers including corporations, governments, financial institutions, and individuals. It operates through the following segments: Institutional Securities, Wealth Management, and Investment Management. The Institutional Services segment provides financial advisory, capital-raising services, and related financing services on behalf of institutional investors. The Wealth Management segment offers brokerage and investment advisory services covering various types of investments, including equities, options, futures, foreign currencies, precious metals, fixed-income securities, mutual funds, structured products, alternative investments, unit investment trusts, managed futures, separately managed accounts, and mutual fund asset allocation programs. The Investment Management segment provides equity, fixed income, alternative investments, real estate, and merchant banking strategies. The company was founded by Harold Stanley and Henry S. Morgan in 1924 and is headquartered in New York, NY.

Morgan Stanley

Morgan Stanley ($MS) is trending amid discussions around bank regulations, potential M&A activity, and analysts weighing in on its financial outlook and strategic shifts. The community is focused on institutional ownership, potential earnings catalysts, and its position relative to competitors like Goldman Sachs ($GS). Recent news includes Morgan Stanley expanding crypto access and analysts adjusting price targets, driving both bullish and bearish sentiment.

Polkadot is a platform that allows diverse blockchains to transfer messages, including value, in a trust-free fashion; sharing their unique features while pooling their security. In brief, Polkadot is a scalable heterogeneous multi-chain technology.  Polkadot is heterogeneous because it is entirely flexible and makes no assumption about the nature or structure of the chains in the network. Even non-blockchain systems or data structures can become parachains if they fulfill a set of criteria.  Polkadot may be considered equivalent to a set of independent chains (e.g. a set containing Ethereum, Ethereum Classic, Namecoin and Bitcoin) except with important additions: pooled security and trust-free interchain transactability.  Many of the native parachains of Polkadot will be written using a Polkadot Runtime Environment SDK (e.g. Parity Technologies' Substrate).

Polkadot

Polkadot is trending as the community discusses its long-term potential, interoperability and recent supply cap implementation.  Some investors view it as a solid project for cross-chain applications, while others are weighing its potential against emerging Layer 1 solutions focused on high-speed settlement and compliance.

SSgA Active Trust - Health Care Select Sector SPDR

Health Care Select Sector SPDR Fund

The Health Care Select Sector SPDR Fund ($XLV) is trending amid discussions of sector rotation and potential breakout opportunities, particularly as some analysts suggest a shift from technology into healthcare. Community members are actively trading call options on XLV, targeting higher price levels, while also weighing in on potential impacts from healthcare policy and individual companies within the sector. There is also discussion that a recent top may need to be retested.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.Retry

Cardano

Cardano is trending amid mixed community sentiment, with some expressing frustration over its price performance compared to Bitcoin and other altcoins.  Discussions also involve comparisons to Keeta, highlighting Cardano's methodical approach versus Keeta's focus on high-speed, compliant infrastructure; the potential launch of Midnight token, and speculation around an ADA ETF.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disney is trending as the community digests mixed earnings results, with streaming growth offset by declines in linear TV. Community discussion also centers on Disney's ongoing dispute with YouTube TV and potential impacts from upcoming movie releases like Zootopia 2. Despite some bearish sentiment, analysts are weighing in with price target adjustments, and some investors are seeing a buying opportunity.

SPDR Gold Trust - SPDR Gold Shares ETF

SPDR Gold Shares ETF

SPDR Gold Shares ETF ($GLD) is trending amid discussions around market volatility and potential Federal Reserve actions, with some traders viewing it as a safe haven asset. Community members are analyzing technical patterns and debating whether it's poised for further gains, a correction, or a period of consolidation. Bullish sentiment is fueled by expectations of future rate cuts and gold's historical role as an inflation hedge.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Insider Buying: SELLAS Life Sciences Group (NASDAQ:SLS) Director Purchases 63,400 Shares of Stock

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) Director Katherine Bach Kalin purchased 63,400 shares of the firm's stock in a transaction on Wednesday, November 19th. The stock was...

Katherine Bach Kalin Acquires 63,400 Shares of SELLAS Life Sciences Group (NASDAQ:SLS) Stock

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) Director Katherine Bach Kalin acquired 63,400 shares of the firm's stock in a transaction that occurred on Wednesday, November 19th...

SELLAS Life Sciences Group Sees Unusually Large Options Volume (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) was the target of unusually large options trading on Tuesday. Traders purchased 15,545 call options on the company. This represents an...

SELLAS Life Sciences Group (NASDAQ:SLS) Announces Earnings Results, Beats Expectations By $0.02 EPS

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) posted its earnings results on Wednesday. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus...

<ul class="summary-bullets"><li>The company announced the exercise of existing warrants held by an institutional investor.</li><li>The investor will receive new registered warrants to purchase up to 22.4 million shares of its common stock at an exercise price of $2.00 for the exercise of existing warrants.&nbsp;</li><li>The transaction is expected to close on or about October 28, the company said.&nbsp; &nbsp;</li></ul>Shares of SELLAS Life Sciences Group, Inc. (SLS) slumped 6% on Monday after the company announced the exercise of existing warrants held by an institutional investor for $31 million in gross proceeds.The warrants were previously issued in March and August 2024, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.sellaslifesciences.com/news/News-Details/2025/SELLAS-Life-Sciences-Group-Announces-Exercise-of-Existing-Warrants-Held-by-a-Current-Institutional-Investor-for-31-Million-in-Gross-Proceeds/default.aspx">said</a>. The investor will receive new registered warrants to purchase up to 22.4 million shares of its common stock at an exercise price of $2.00 for the exercise of existing warrants.The new warrants will be exercisable immediately and will expire five years from the date of issuance, the company said.The closing of the translation is expected to occur on or about October 28, it added.Sellas is a late-stage clinical biopharmaceutical company focused on developing novel cancer therapeutics. Its lead product candidate, called GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets a protein present in an array of tumor types.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around<a href="https://stocktwits.com/symbol/SLS"> SLS stock</a> fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.A Stocktwits user recommended holding the stock, opining that it will now go higher.<stembedurl>https://stocktwits.com/Kevoo/message/633843705</stembedurl>Another dismissed concerns of dilution, terming the warrant exercise a “not that big deal.”<stembedurl>https://stocktwits.com/Risulom/message/633841655</stembedurl> In September, the company <a href="https://stocktwits.com/news-articles/markets/equity/sellas-life-sciences-stock-in-spotlight-after-institutional-investor-exercises-existing-warrants/chwNYhvRdvv">announced</a> that an institutional investor had exercised the warrants it held to purchase up to 19.69 million shares of the company’s common stock for gross cash proceeds of approximately $23.6 million. The warrants were previously issued in January 2025, the company then said.SLS stock is up by 80% this year and by about 54% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/dyne-therapeutics-stock-soars-after-rival-avidity-biosciences-gets-acquired-by-novartis/cLG0X2XR3u7">Dyne Therapeutics Stock Soars After Rival Avidity Biosciences Gets Acquired By Novartis</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

Why Is SELLAS Life Sciences Stock Falling Today?

Shares of SELLAS Life Sciences Group, Inc. (SLS) slumped 5% on Monday after the company announced the exercise of existing warrants held by an institutional investor for $31 million in gross proceeds.

Why Is SELLAS Life Sciences (SLS) Stock Falling Today?

Equity

Shares of Sellas Life Sciences rose over 7% in premarket trading on Thursday as investors turned optimistic ahead of the company’s Saturday presentation on new preclinical data for its experimental cancer drug SLS009 at the European Society for Medical Oncology Congress 2025 in Berlin.Promising Data In Rare Leukemia&nbsp;Sellas said its selective CDK9 inhibitor, SLS009, showed significant activity in treating T-cell prolymphocytic leukemia (T-PLL), both as a standalone therapy and in combination with venetoclax.&nbsp;In a patient-derived xenograft model of relapsed or refractory T-PLL, SLS009 monotherapy extended survival to 7.4 weeks, while the combination reached 7.9 weeks, compared with 4.4 weeks for venetoclax alone, marking a statistically significant improvement. The company said both regimens also reduced circulating T-PLL cells more effectively and were well tolerated.&nbsp;Faster Clinical TranslationDragan Cicic, Chief Development Officer at Sellas, said the findings provide “important preclinical evidence” that CDK9 inhibition may play a key role in addressing this aggressive and difficult-to-treat leukemia.Francisco Vega of the University of Texas MD Anderson Cancer Center, the study’s lead author, said the new T-PLL xenograft model “closely mirrors” the behavior and progression of the disease in humans. It allows for faster translation of promising preclinical data into the clinic.Pipeline Expands Beyond LeukemiaSLS009 is one of Sellas’ key oncology assets, alongside its lead WT1-targeting immunotherapy, GPS, licensed from Memorial Sloan Kettering Cancer Center. The company said both candidates are designed to address cancers with poor prognostic factors and limited treatment options.Stocktwits Bulls Cheer Upcoming PresentationOn Stocktwits, retail sentiment for Sellas was ‘extremely bullish’ amid a 50% surge in 24-hour message volume.One user cheered the global attention around the stock, noting strong overnight interest and hinting at excitement ahead of the company’s planned Virtual R&amp;D Day on Oct.29.<stembedurl>https://stocktwits.com/Hannibal_Smith/message/632520690</stembedurl>Another said they hoped Sellas would release both the new data and a buyout announcement at the same event, joking that such a move could send the stock straight to 125 a share.<stembedurl>https://stocktwits.com/Mazzy85/message/632517776</stembedurl><a href="https://stocktwits.com/symbol/SLS">Sellas’ stock</a> has more than doubled so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Sellas’ stock (SLS) has more than doubled so far in 2025. | Image source: Getty Images

Sellas Life Sciences Stock Jumps Over 7% Premarket: Buzz Builds Ahead Of Weekend Cancer Drug Presentation In Berlin

The company said its cancer drug SLS009 showed strong preclinical results in T-cell prolymphocytic leukemia, improving survival and reducing tumor burden both alone and in combination with venetoclax. 

SELLAS Life Sciences Group (SLS) announced on Monday that preclinical data support its SLS009 as a monotherapy or in combination with Venetoclax for treating a rare and highly aggressive form of mature T-cell leukemia.The biopharmaceutical company said that data supporting the drug in T-cell prolymphocytic leukemia will be presented at the European Society for Medical Oncology Congress 2025, being held October 17 to October 21, in Berlin, Germany. T-PLL or T-cell prolymphocytic leukemia is a rare, aggressive type of mature T-cell leukemia that primarily affects older adults, characterized by the rapid growth of cancerous T-cells.SELLAS <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.sellaslifesciences.com/news/News-Details/2025/SELLAS-Life-Sciences-to-Present-In-Vivo-Preclinical-Data-Demonstrating-Statistically-Significant-Survival-Benefit-of-SLS009-in-T-Cell-Prolymphocytic-Leukemia-at-the-European-Society-for-Medical-Oncology-ESMO-Congress-2025/default.aspx">said</a> that in a study model, SLS009 monotherapy and the combination prolonged overall survival compared to Venetoclax alone, with a statistically significant difference. The combination regimen, which prolonged overall survival to 7.9 weeks, was also well tolerated in the study, the company said.Chief Development Officer at SELLAS, Dragan Cicic, said that the results from the study are “highly encouraging” and noted that T-PLL has minimal treatment options.SLS shares traded 5% higher at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SLS">SLS stock</a> remained in the ‘bullish’ territory, while message volume increased from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:622/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_13_at_11_30_56_AM_png_b0f4827381.webp" alt="SLS's Sentiment Meter and Message Volume as of 11:30 a.m. ET on Oct. 13, 2025 | Source: Stocktwits" width="622" height="61"><figcaption>SLS's Sentiment Meter and Message Volume as of 11:30 a.m. ET on Oct. 13, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user wondered why the stock didn’t rally further on the news.<stembedurl>https://stocktwits.com/SunnySeed/message/632108231</stembedurl>SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications.SLS stock has nearly doubled this year and is up about 60% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/whats-driving-the-rally-in-ndra-stock-today/ch6Sk9VR3kY">What’s Driving The Rally In NDRA Stock Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

SELLAS Life Sciences Stock Rises On Strong Preclinical Data For Investigational Cancer Treatment

SELLAS said that in a study model, SLS009 monotherapy and the combination prolonged overall survival compared to Venetoclax alone, with a statistically significant difference.

Sellas Life Sciences Group, Inc. (SLS) on Thursday announced that an institutional investor has exercised the warrants it held to purchase up to 19.69 million shares of the company’s common stock for gross cash proceeds of approximately $23.6 million. The warrants were previously issued in January 2025.In consideration for the immediate exercise of the warrants in full, the investor will receive new unregistered warrants in a private placement to purchase up to 19.69 million shares of its common stock at an exercise price of $1.88. These warrants will be exercisable immediately and will expire five years and six months from the date of issuance, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.sellaslifesciences.com/news/News-Details/2025/SELLAS-Life-Sciences-Group-Announces-Exercise-of-Existing-Warrants-Held-by-a-Current-Institutional-Investor-for-23-6-Million-in-Gross-Proceeds/default.aspx">said</a>.The closing of the transaction is expected to occur on or about Sept. 12, 2025, subject to satisfaction of customary closing conditions.Sellas is a late-stage clinical biopharmaceutical company focused on developing novel therapeutics for cancer. Its lead product candidate, called GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets a protein present in an array of tumor types. The company is also developing SLS009 in the treatment of Acute Myeloid Leukemia. &nbsp;On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SLS">SLS stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume stayed within ‘normal’ levels. Shares of the company were fell over 2% at the time of writing.<figure class="image"><img style="aspect-ratio:576/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_11_at_12_33_53_PM_png_42e9b0a3c2.webp" alt="SLS's Sentiment Meter and Message Volume as of 12:34 p.m. ET on Sept. 11, 2025 | Source: Stocktwits" width="576" height="60"><figcaption>SLS's Sentiment Meter and Message Volume as of 12:34 p.m. ET on Sept. 11, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user sounded skeptical about the new warrants.<stembedurl>https://stocktwits.com/RandomInvestor777/message/628334051</stembedurl>Another user noted they have added to their position.<stembedurl>https://stocktwits.com/SomedayisNow/message/628326459</stembedurl>SLS stock is up 76% this year and approximately 39% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/wolfpack-research-reveals-short-position-in-faraday-future/chwNmHARdvm">Wolfpack Research Reveals Short Position In EV Maker Faraday Future</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Sellas Life Sciences Stock In Spotlight After Institutional Investor Exercises Existing Warrants

In consideration for the immediate exercise of the warrants in full, the institutional investor will receive new, unregistered warrants in a private placement to purchase up to 19.69 million shares of the company's common stock.

In consideration for the immediate exercise of the warrants in full, the institutional investor will receive new, unregistered warrants in a private placement to purchase up to 19.69 million shares of the company's common stock at an exercise price of $1.88. 


SELLAS Life Sciences Group (SLS) Upgraded to Buy: What Does It Mean for the Stock? (Revised)

SELLAS Life Sciences Group (SLS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Galena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock?

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

$AMZN

$MSFT

$GOOGL

$ORCL

Which cloud infrastructure stock offers the best long-term opportunity right now?

SLS
SELLAS Life Sciences Group Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest SLS News

SLSSELLAS Life Sciences Group Inc